Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies
Judicial Panel on Multidistrict Litigation (JPML) is set to hear arguments on January 30, 2025, about consolidating federal lawsuits related to Depo-Provera into a single multidistrict litigation (MDL)
The Importance of the Free Assessment Quiz If you are feeling stuck or confused about which medication is right for you, the best next step is professional evaluation
DSIP Delta Sleep-Inducing Peptide Overview Delta sleep-inducing peptide (DSIP) is a naturally occurring nonapeptide with neuromodulatory activity that has been a focus of research for over four decades
By connecting you with licensed providers who can prescribe personalized treatmentsincluding compounded semaglutide or tirzepatide shipped from inspected pharmacieswe ensure your journey is medically supervised every step of the way
